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Edited by Robert BaroukiAbstract Recent epidemiological studies demonstrated a beneﬁ-
cial eﬀect of coﬀee consumption for the prevention of type 2 dia-
betes, however, the underlying mechanisms remained unknown.
We demonstrate that coﬀee extract, corresponding to an Italian
Espresso, inhibits recombinant and endogenous 11b-hydroxyster-
oid dehydrogenase type 1 (11b-HSD1) activity. The inhibitory
component is heat-stable with considerable polarity. Coﬀee
extract blocked 11b-HSD1-dependent cortisol formation,
prevented the subsequent nuclear translocation of the glucocorti-
coid receptor and abolished glucocorticoid-induced expression of
the key gluconeogenic enzyme phosphoenolpyruvate carboxyki-
nase. We suggest that at least part of the anti-diabetic eﬀects
of coﬀee consumption is due to inhibition of 11b-HSD1-depen-
dent glucocorticoid reactivation.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Coﬀee is one of the most often consumed beverages world-
wide. Recently, several population studies demonstrated an
association of coﬀee consumption with improved glucose toler-
ance and insulin sensitivity and a lower risk of type 2 diabetes
[1,2]. Constituents other than caﬀeine seem to be responsible
for the anti-diabetic eﬀects of coﬀee, however, neither the ac-
tive compound nor the responsible target have been identiﬁed
so far.
Based on a series of animal experiments and observations
from studies with humans, it became evident that excessive glu-
cocorticoid action plays a causal role in the pathogenesis of
type 2 diabetes and metabolic syndrome [3,4]. In particular,
the enhanced local conversion of inactive 11-ketog-
lucocorticoids (cortisone, 11-dehydrocorticosterone) to active
11b-hydroxyglucocorticoids (cortisol, corticosterone) by 11b-
HSD1 in metabolically active tissues such as liver, adipose tis-
sue and skeletal muscle has been implicated in these disorders*Corresponding author. Fax: +41 31 632 9444.
E-mail address: alex.odermatt@dkf.unibe.ch (A. Odermatt).
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doi:10.1016/j.febslet.2006.06.046[5–7]. Whereas 11b-HSD1 knock-out mice were resistant to
high fat diet-induced metabolic syndrome [8,9], mice speciﬁ-
cally overexpressing 11b-HSD1 in adipose tissue showed all
typical features of the metabolic syndrome [10,11]. Mice over-
expressing 11b-HSD1 in the liver developed insulin resistance,
dyslipidemia, and hypertension, but they were not obese [12].
Moreover, several studies reported an elevated 11b-HSD1
expression in adipose tissue of obese patients [5].
Treatment of obese and diabetic mouse strains with selective
11b-HSD1 inhibitors resulted in a signiﬁcant improvement of
glucose tolerance and insulin sensitivity, accompanied with re-
duced visceral fat deposits [13–15]. These studies suggest that
inhibition or downregulation of 11b-HSD1 provides beneﬁcial
eﬀects opposing the onset of metabolic syndrome [16].
We previously demonstrated the existence of natural com-
pounds selectively inhibiting 11b-HSD1, e.g. ﬂavanone and
2 0-hydroxyﬂavanone present in red and yellow fruits and veg-
etables [17]. Because coﬀee is a rich source of biologically ac-
tive compounds [18] and because of its anti-diabetic eﬀect,
we tested the hypothesis whether coﬀee contains compounds
inhibiting 11b-HSD1 activity.2. Materials and methods
2.1. Preparation of coﬀee extract
To prepare a coﬀee extract with a composition corresponding to that
of an Italian Espresso, 10 g of freshly grinded roasted beans of Coﬀea
Arabica L. were extracted with 30 ml of water for 15 s at 100 C and a
pressure of 15 bar. After sterile ﬁltration, aliquots of the ﬁltrate were
frozen at 20 C and stored until further analysis. To assess the eﬀect
of charcoal treatment on the inhibitory eﬀect of the coﬀee extract,
10 ml of extract was incubated with 50 mg of activated charcoal for
10 min under stirring, followed by ﬁltration. This procedure was re-
peated three times and the inhibitory potential of the stripped extract
on 11b-HSD1 activity was measured. For the liquid/liquid extraction,
500 ll extract was mixed with 500 ll of the corresponding organic sol-
vent (n-hexane, dichloromethane or ethyl acetate), followed by vigor-
ous mixing for 10 s and incubation for 10 min. The water and
organic phase were separated after centrifugation for 10 min at
10000 · g.
2.2. 11b-HSD1 activity assays
Recombinant 11b-HSD1 was expressed in HEK-293 cells and enzy-
matic activities were measured in cell lysates and in intact cells as de-
scribed previously [17,19]. Brieﬂy, frozen cell pellets were resuspended
in ice-cold buﬀer TS2 (100 mM NaCl, 1 mM EGTA, 1 mM EDTA,
1 mM MgCl2, 250 mM sucrose, 20 mM Tris–HCl, pH 7.4) and soni-
cated. Reactions were carried out for 10 min at 37 C in a ﬁnal volumeblished by Elsevier B.V. All rights reserved.
Fig. 1. Inhibition of 11b-HSD1 activity by coﬀee extracts. Inhibition
of 11b-HSD1-dependent conversion of cortisone to cortisol by various
concentrations of coﬀee extract was measured in cell lysates (open
circles) and intact HEK-293 cells (ﬁlled squares) expressing recombi-
nant 11b-HSD1. Data represent mean ± S.D. from at least four
independent experiments.
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beled Chemicals, St. Louis, MO, USA), 250 nM unlabeled cortisone,
400 lMNADPH and diﬀerent amounts of coﬀee extract. For measure-
ments in intact cells, 50000 transfected cells per well were seeded in
poly-D-lysine coated 96-well Biocoat plates (Becton–Dickinson, Basel,
Switzerland). The medium was replaced 24 h later by 80 ll fresh med-
ium, 10 ll medium containing various concentrations of coﬀee extract
and 10 ll medium containing 10 nCi [1,2,6,7-3H]-cortisone and
250 nM unlabeled cortisone. Cells were incubated for 2 h at 37 C un-
der 5% CO2, reactions stopped by adding an excess of unlabeled corti-
sone and cortisol in methanol, followed by separation of steroids by
TLC and determination of the conversion of radiolabeled substrate
by scintillation counting. Data (mean ± S.D.) were obtained from at
least four independent experiments.
2.3. Glucocorticoid receptor translocation assay
HEK-293 cells (300000 cells/well) were grown on poly(L-lysine)-
coated glass slides in six-well plates containing 2 ml DMEM med-
ium. Cells were transfected by calcium phosphate precipitation, with
1 lg/well of a plasmid for green-ﬂuorescent (GFP)-tagged human
GR [20] and 1 lg/well of a plasmid for human 11b-HSD1 [21].
To remove steroids, cells were washed twice with charcoal-treated
DMEM 6 h post-transfection, followed by incubation for another
16 h. Cells were then incubated for 40 min with cortisone, cortisol,
coﬀee extract or vehicle as indicated. After rinsing the cells with
phosphate-buﬀered saline and ﬁxation for 10 min with 4% parafor-
maldehyde, the subcellular localization of GFP-GR was detected
by ﬂuorescence microscopy.
2.4. Analysis of phosphoenolpyruvate carboxykinase mRNA expression
Currently, there is no suitable liver cell line available that expresses
11b-HSD1, and 11b-HSD1 activity disappears upon cultivation of pri-
mary hepatocytes. To study the eﬀect of hepatic 11b-HSD1-dependent
glucocorticoid reactivation on the regulation of the gluconeogenic en-
zyme phosphoenolpyruvate carboxykinase (PEPCK), we applied rat
H4EII hepatoma cells stably expressing mouse 11b-HSD1 [22]. These
cells were kindly provided by Dr. Kurt Amrein, Hoﬀmann LaRoche,
Basel. Cells were cultured in MEM medium, followed by incubation
in serum-free MEM. Coﬀee extract at concentrations indicated were
added 15 min prior addition of 50 nM cortisone, and cells were har-
vested after incubation for 3 h at 37 C. The mRNA levels were deter-
mined by real-time RT-PCR using TaqMan technology as described
previously [23]. The relative expression of PEPCK mRNA was deter-
mined versus b-actin as control. Data represent mean ± S.D. deter-
mined from triplicates.Fig. 2. The active compound is heat-stable and binds to charcoal.
Prior to subjection to the 11b-HSD1 activity assay, the coﬀee extract
was boiled for 30 min or pretreated with charcoal.3. Results
3.1. Coﬀee extract inhibits 11b-HSD1 activity
To test our hypothesis that coﬀee beverage contains com-
pounds with anti-diabetic eﬀects due to decreased local gluco-
corticoid reactivation, we prepared a coﬀee extract with a
composition similar to that of an Italian Espresso and tested
its eﬀect on 11b-HSD1-dependent conversion of cortisone to
cortisol. The presence of coﬀee extract at a ﬁnal concentration
of 1% almost completely inhibited the 11b-HSD1-dependent
oxoreduction of cortisone in cell lysates (Fig. 1). Upon incuba-
tion with various concentrations of coﬀee extract, a dose-
dependent inhibition curve with an IC50 of approximately
0.25% was observed in cell lysates and of 0.7% in intact cells.
Coﬀee extract similarly inhibited 11b-HSD1 activity in fully
diﬀerentiated mouse 3T3-L1 adipocytes and in mouse C2C12
myotubes (not shown), two metabolically relevant endogenous
cell models [24]. Inhibition of 11b-HSD1 was 7–10-fold more
eﬃcient than that of 11b-HSD2 and 17b-HSD1 (not shown),
indicating that coﬀee preferentially inhibits glucocorticoid
reactivation. Comparable results were obtained with ﬁve diﬀer-
ent commercially available coﬀee brands, while extracts fromcocoa powder, which is also a rich source of polyphenolic com-
pounds, did not inhibit 11b-HSD1.
3.2. Exclusion of caﬀeine as the 11b-HSD1 inhibitor
Next, we measured the eﬀect of extracts from decaﬀeinated
coﬀee on 11b-HSD1 activity and obtained an inhibition com-
parable to that of normal coﬀee extract. Moreover, 2 mM of
pure caﬀeine did not aﬀect 11b-HSD1 activity. We also found
no inhibitory eﬀect with 200 lM of caﬀeic acid, chlorogenic
acid or trigonelline, three well-known biologically active sub-
stances present in coﬀee beverage (not shown).
3.3. Chemical properties of the inhibitory compound
We performed experiments to obtain initial information on
the stability and polarity of the inhibitory compound. Boiling
of the aqueous coﬀee extract for 30 min did not aﬀect its eﬀect,
Fig. 3. Partition of the inhibitory compound in diﬀerent solvent
systems. The aqueous coﬀee extract was mixed thoroughly with an
equal volume of n-hexane, dichloromethane or ethyl acetate. After
separation of both phases, their inhibitory potential was determined by
measuring 11b-HSD1 activity in cell lysates in the presence of 0.5% of
the corresponding phase. The presence of 0.5% of any of the solvents
tested did not aﬀect the enzymatic reaction.
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inhibitory eﬀect of the extract was abolished, however, upon
charcoal treatment. To further assess the solubility of the
inhibitor, the aqueous coﬀee extract was mixed with an equal
volume of the organic solvents n-hexane, dichloromethane,
or ethyl acetate, followed by separation of the two phases
and determination of the presence of the inhibitory substance
in both phases (Fig. 3). An equal partition was obtained with
water/ethyl acetate, whereas highly hydrophobic solvents such
as n-hexane extracted only small amounts of the inhibitor.
These observations and the fact that it is solubilized from cof-
fee beans with water suggest that the inhibitor is a fairly polar
compound.
3.4. Blockade of 11b-HSD1-mediated GR activation by coﬀee
extract
We tested the eﬀect of coﬀee extract on the 11b-HSD1-
dependent conversion of inactive cortisone to active cortisol
and the subsequent induction of nuclear translocation of the
GR. In the inactive state the GR resides in the cytoplasm.
Upon binding cortisol it undergoes a conformational activa-
tion and translocates into the nucleus where it regulates genes
with a GR-response element (GRE). As shown in Fig. 4, incu-
bation of HEK-293 cells expressing GFP-GR and 11b-HSD1
with cortisone led to almost complete translocation of the
receptor into the nucleus. Simultaneous incubation with coﬀee
extract abolished nuclear receptor translocation, indicating
inhibition of 11b-HSD1-dependent conversion of cortisone
to cortisol. That the eﬀect of coﬀee extract was due to inhibi-
tion of 11b-HSD1 is indicated by the lack of a direct eﬀect
of the extract to prevent cortisol-induced GR activation.
Furthermore, we assessed the eﬀect of the inhibition of 11b-
HSD1-dependent cortisol formation on the glucocorticoid-
dependent expression of PEPCK (Fig. 5). Addition of 50 nM
cortisone resulted in a 6-fold stimulation of PEPCK mRNAFig. 4. Glucocorticoid receptor translocation assay. HEK-293 cells expressin
500 nM cortisone, and with 1.5% of coﬀee extract and either 500 nM co
ﬂuorescence microscopy to detect GFP-GR (green ﬂuorescence) and DAPIexpression after a three hour incubation. Treatment of cells
with increasing concentrations of coﬀee extract abolished glu-
cocorticoid-induced PEPCK expression.g GFP-GR and 11b-HSD1 were treated with vehicle (control panel),
rtisone or cortisol, respectively, for 40 min. Cells were analyzed by
for nuclear staining (blue ﬂuorescence).
Fig. 5. Coﬀee extract prevents glucocorticoid-dependent stimulation
of PEPCK mRNA expression by inhibition of 11b-HSD1. H4EII
hepatoma cells stably expressing 11b-HSD1 were incubated with
50 nM cortisone in the presence or absence of various amounts of
coﬀee extract for 3 h. The levels of mRNA were determined by real-
time RT-PCR using TaqMan technology. Data represent mean ± S.D.
from triplicates and are relative to the ratio of PEPCK mRNA to the
b-actin control mRNA of untreated cells (control).
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A number of recent human population studies associated
coﬀee consumption with a reduced risk for the development
of type 2 diabetes [1], suggesting that coﬀee might be regarded
as ‘‘functional food’’ for the prevention of metabolic disease
[25]. However, little progress has been made so far in elucidat-
ing the mechanisms underlying the anti-diabetic eﬀect of coﬀee
drinking. It became clear that this eﬀect is not related to caf-
feine itself, since consumption of decaﬀeinated coﬀee also ex-
erted an anti-diabetic eﬀect [26,27]. Moreover, although for a
long time most of the biological eﬀects of coﬀee beverage have
been referred to as pure caﬀeine eﬀects, a recent study indi-
cated that acute caﬀeine ingestion impairs glucose tolerance
while regular consumption of caﬀeinated or decaﬀeinated cof-
fee beverage exerts a protective eﬀect against type 2 diabetes
[28].
Some biologically active ingredients of coﬀee that were sug-
gested to contribute to its anti-diabetic actions are chlorogenic
acid – through reduced glucose absorption and increased pro-
duction of glucagon-like peptide 1 [29], lignans – through anti-
oxidant and estrogenic activity [30], and trigonelline, which
was shown to lower blood glucose levels by yet unknown
mechanisms. However, none of these ingredients seems to be
responsible for the anti-diabetic eﬀects of regular coﬀee intake
[2].
It is generally accepted that excessive glucocorticoid action
plays an important role in the pathogenesis of obesity and type
2 diabetes. Many features of the metabolic syndrome are ob-
served in patients with Cushing’s syndrome due to excessive
glucocorticoid production as a result of adrenal tumors or be-
cause of prolonged treatment with high pharmacologic doses
[31]. In obese individuals, however, systemic glucocorticoid
levels are not signiﬁcantly elevated, but an increased local reac-
tivation of glucocorticoids in adipose tissue and in skeletalmuscle has been associated with the pathogenesis of the meta-
bolic syndrome [32]. Importantly, recent studies demonstrated
a signiﬁcant improvement of glucose tolerance and insulin sen-
sitivity in obese and diabetic animals treated with synthetic
11b-HSD1 inhibitors [13–15].
We previously reported the existence of natural compounds
inhibiting 11b-HSD1 [17]. Flavanone and 2 0-hydroxyﬂava-
none, present in red and yellow fruits and vegetables, inhibited
11b-HSD1 oxoreductase activity in lysates and intact cells
without inhibiting the related enzymes 11b-HSD2, 17b-
HSD1 or 17b-HSD2. A recent in silico screening of a library
of 114000 natural compounds conducted by researchers at
the Nestle Research Center yielded several ﬂavanone deriva-
tives, not speciﬁed further, that ﬁtted into the substrate-bind-
ing pocket of 11b-HSD1 [33]. Coﬀee is an extraordinarily
rich source of biologically active compounds, however, only
very few compounds have been studied more extensively so
far.
The present study suggests the presence of a thermo-stable
substance with considerable polarity – a proﬁle that suits a
polyphenolic or ﬂavonoid-like compound. Our results clearly
demonstrate the presence of relevant amounts of compound(s)
in coﬀee beverage that inhibit 11b-HSD1-dependent reactiva-
tion of glucocorticoids, thereby reducing the activation of
the GR. Moreover, using a liver cell model, we provide evi-
dence that coﬀee-induced inhibition of 11b-HSD1 decreases
hepatic gluconeogenesis. Nevertheless, further experiments
are required to identify the compound(s) responsible for the
observed eﬀects and to test their eﬀects on glucose tolerance
and insulin sensitivity in vivo.
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